The UPC was met with caution by the life science sector. Nevertheless, new data from its first two years shows a changing reality - pharmaceutical and chemistry-related litigation is not only present, it’s gaining momentum. This session will offer a deep dive into the UPC’s evolving role in high-stakes life science patent disputes, helping you prepare an informed strategy for 2025 and beyond.
• Understand the latest UPC litigation statistics and what they reveal about pharma and chemistry sector adoption.
• Discover why Milan and Munich are emerging as key venues for life science disputes and what it means for your forum selection.
• Learn how English-language dominance is shaping litigation strategy for multinational teams.
• Analyse how early UPC case law is influencing industry confidence and what your business risks by staying on the sidelines.
• Hear how to coordinate UPC proceedings with EPO oppositions to build an integrated and effective litigation approach.
James Robertson
